MA34560B1 - Particules inhalables contenant du tiotropium - Google Patents
Particules inhalables contenant du tiotropiumInfo
- Publication number
- MA34560B1 MA34560B1 MA33805A MA33805A MA34560B1 MA 34560 B1 MA34560 B1 MA 34560B1 MA 33805 A MA33805 A MA 33805A MA 33805 A MA33805 A MA 33805A MA 34560 B1 MA34560 B1 MA 34560B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhalable particles
- particles containing
- tiotropium
- relates
- stabilizing agent
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 6
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title abstract 3
- 229940110309 tiotropium Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Electrolytic Production Of Metals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention porte sur des particules inhalables contenant une forme amorphe stabilisée de tiotropium avec un agent stabilisant. L'invention concerne également des particules inhalables contenant une forme amorphe stabilisée de tiotropium avec un agent stabilisant, mélangée à un ou plusieurs gros excipients d'une taille particulaire moyenne comprise entre 15 et 250 µm. L'invention porte en outre sur une composition pharmaceutique contenant les particules inhalables de l'invention, sur un procédé de préparation correspondant, ainsi que sur l'utilisation de ces particules dans la préparation d'un médicament destiné au traitement de l'asthme ou de la broncho-pneumopathie chronique obstructive (BPCO).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08382040A EP2172190A1 (fr) | 2008-10-02 | 2008-10-02 | Particules inhalables comprenant du tiotropium |
| US10411308P | 2008-10-09 | 2008-10-09 | |
| PCT/EP2009/062821 WO2010037845A1 (fr) | 2008-10-02 | 2009-10-02 | Particules inhalables contenant du tiotropium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34560B1 true MA34560B1 (fr) | 2013-10-02 |
Family
ID=40348057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33805A MA34560B1 (fr) | 2008-10-02 | 2009-10-02 | Particules inhalables contenant du tiotropium |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US20110311618A1 (fr) |
| EP (2) | EP2172190A1 (fr) |
| JP (1) | JP5622730B2 (fr) |
| KR (1) | KR101639089B1 (fr) |
| CN (1) | CN102170861B (fr) |
| AR (1) | AR073528A1 (fr) |
| AU (1) | AU2009299801B2 (fr) |
| BR (1) | BRPI0920706B8 (fr) |
| CA (1) | CA2737399C (fr) |
| CL (1) | CL2011000696A1 (fr) |
| CO (1) | CO6361899A2 (fr) |
| CR (1) | CR20110227A (fr) |
| CY (1) | CY1121090T1 (fr) |
| DK (1) | DK2349204T3 (fr) |
| DO (1) | DOP2011000091A (fr) |
| EC (1) | ECSP11010925A (fr) |
| ES (1) | ES2675857T3 (fr) |
| HN (1) | HN2011000864A (fr) |
| HR (1) | HRP20181009T1 (fr) |
| HU (1) | HUE038208T2 (fr) |
| LT (1) | LT2349204T (fr) |
| MA (1) | MA34560B1 (fr) |
| MX (1) | MX2011003491A (fr) |
| MY (1) | MY159172A (fr) |
| NI (1) | NI201100066A (fr) |
| NZ (1) | NZ591923A (fr) |
| PE (2) | PE20142435A1 (fr) |
| PL (1) | PL2349204T3 (fr) |
| PT (1) | PT2349204T (fr) |
| RU (2) | RU2685236C2 (fr) |
| SI (1) | SI2349204T1 (fr) |
| SM (1) | SMT201800350T1 (fr) |
| SV (1) | SV2011003852A (fr) |
| TR (1) | TR201808269T4 (fr) |
| TW (1) | TWI433675B (fr) |
| UA (1) | UA100777C2 (fr) |
| UY (1) | UY32160A (fr) |
| WO (1) | WO2010037845A1 (fr) |
| ZA (1) | ZA201101735B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2552414A4 (fr) * | 2010-03-31 | 2014-05-14 | Glenmark Pharmaceuticals Ltd | Composition de poudre pharmaceutique pour inhalation |
| EP2575786B1 (fr) * | 2010-06-03 | 2017-11-15 | Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. | Procédé pour formulations pulvérulentes sèches |
| WO2011154014A1 (fr) * | 2010-06-11 | 2011-12-15 | Gea Process Engineering A/S | Séchage contrôlé de l'humidité |
| NZ607358A (en) | 2010-08-23 | 2015-04-24 | Takeda Gmbh | Humidified particles comprising a therapeutically active substance |
| WO2013109216A2 (fr) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Préparation de formulations en poudre sèche comprenant du tiotropium |
| US9387616B2 (en) | 2012-08-03 | 2016-07-12 | Otto Männer Innovation GmbH | Hot runner injection molding apparatus with additional controller |
| EP2705838A1 (fr) * | 2012-09-06 | 2014-03-12 | Xspray Microparticles Ab | Préparations de tiotropium |
| KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| KR101748796B1 (ko) * | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | 활성성분의 전달량이 향상된 흡입용 캡슐제 |
| CN109789131B (zh) * | 2016-09-19 | 2022-08-26 | 墨西哥氟石股份公司 | 药物组合物 |
| EP4108230A1 (fr) * | 2021-06-24 | 2022-12-28 | Laboratoires SMB | Nouvelle composition de poudre sèche de tiotropium pour inhalation |
| GR1010358B (el) * | 2021-09-14 | 2022-12-16 | Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, | Σταθερο φαρμακευτικο σκευασμα που περιεχει βρωμιουχο τιοτροπιο, για χορηγηση απο το αναπνευστικο |
| CN114191418B (zh) * | 2021-12-21 | 2023-06-09 | 丽珠医药集团股份有限公司 | 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| CN1150895C (zh) * | 1998-11-13 | 2004-05-26 | 杰格研究股份公司 | 用于吸入给药的干粉 |
| US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
| AP1712A (en) | 2000-10-12 | 2007-01-24 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder |
| EP1591121B1 (fr) * | 2000-12-14 | 2009-06-24 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Procédé pour la préparation des produits à base d'hormone stéroide et leurs procédés de fabrication |
| US6485279B2 (en) * | 2000-12-26 | 2002-11-26 | Carrier Corporation | Thrust load reliever |
| DE10126924A1 (de) * | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalationskapseln |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| CA2478974C (fr) * | 2002-03-20 | 2014-12-16 | Advanced Inhalation Research, Inc. | Formulations therapeutiques soutenues respirables |
| DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| PT1869035E (pt) * | 2005-12-19 | 2013-01-10 | Sicor Inc | Novas formas de brometo de tiotrópio e processos para sua preparação |
| EP1976486A1 (fr) * | 2006-01-27 | 2008-10-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Procede de production de microparticules poreuses |
| GB0716026D0 (en) * | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
-
2008
- 2008-10-02 EP EP08382040A patent/EP2172190A1/fr not_active Withdrawn
-
2009
- 2009-09-30 AR ARP090103794A patent/AR073528A1/es not_active Application Discontinuation
- 2009-10-01 TW TW098133428A patent/TWI433675B/zh active
- 2009-10-02 ES ES09783687.8T patent/ES2675857T3/es active Active
- 2009-10-02 HU HUE09783687A patent/HUE038208T2/hu unknown
- 2009-10-02 WO PCT/EP2009/062821 patent/WO2010037845A1/fr not_active Ceased
- 2009-10-02 BR BRPI0920706A patent/BRPI0920706B8/pt active IP Right Grant
- 2009-10-02 AU AU2009299801A patent/AU2009299801B2/en active Active
- 2009-10-02 MY MYPI2011001426A patent/MY159172A/en unknown
- 2009-10-02 US US13/122,134 patent/US20110311618A1/en not_active Abandoned
- 2009-10-02 KR KR1020117010097A patent/KR101639089B1/ko active Active
- 2009-10-02 DK DK09783687.8T patent/DK2349204T3/en active
- 2009-10-02 PT PT97836878T patent/PT2349204T/pt unknown
- 2009-10-02 PE PE2014002239A patent/PE20142435A1/es active IP Right Grant
- 2009-10-02 EP EP09783687.8A patent/EP2349204B1/fr active Active
- 2009-10-02 RU RU2014150986A patent/RU2685236C2/ru active
- 2009-10-02 RU RU2011117256/15A patent/RU2011117256A/ru unknown
- 2009-10-02 TR TR2018/08269T patent/TR201808269T4/tr unknown
- 2009-10-02 CN CN200980138843.5A patent/CN102170861B/zh active Active
- 2009-10-02 CA CA2737399A patent/CA2737399C/fr active Active
- 2009-10-02 HR HRP20181009TT patent/HRP20181009T1/hr unknown
- 2009-10-02 LT LTEP09783687.8T patent/LT2349204T/lt unknown
- 2009-10-02 SM SM20180350T patent/SMT201800350T1/it unknown
- 2009-10-02 MA MA33805A patent/MA34560B1/fr unknown
- 2009-10-02 UY UY0001032160A patent/UY32160A/es active IP Right Grant
- 2009-10-02 SI SI200931854T patent/SI2349204T1/en unknown
- 2009-10-02 MX MX2011003491A patent/MX2011003491A/es active IP Right Grant
- 2009-10-02 NZ NZ591923A patent/NZ591923A/en unknown
- 2009-10-02 UA UAA201105365A patent/UA100777C2/ru unknown
- 2009-10-02 JP JP2011529566A patent/JP5622730B2/ja active Active
- 2009-10-02 PL PL09783687T patent/PL2349204T3/pl unknown
- 2009-10-02 PE PE2011000799A patent/PE20110850A1/es not_active Application Discontinuation
-
2011
- 2011-03-07 ZA ZA2011/01735A patent/ZA201101735B/en unknown
- 2011-03-07 SV SV2011003852A patent/SV2011003852A/es unknown
- 2011-03-29 EC EC2011010925A patent/ECSP11010925A/es unknown
- 2011-03-30 CL CL2011000696A patent/CL2011000696A1/es unknown
- 2011-03-31 HN HN2011000864A patent/HN2011000864A/es unknown
- 2011-04-01 NI NI201100066A patent/NI201100066A/es unknown
- 2011-04-01 DO DO2011000091A patent/DOP2011000091A/es unknown
- 2011-04-29 CR CR20110227A patent/CR20110227A/es unknown
- 2011-04-29 CO CO11052660A patent/CO6361899A2/es not_active Application Discontinuation
-
2018
- 2018-07-04 CY CY181100703T patent/CY1121090T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ostenfeld et al. | A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction | |
| MA27630A1 (fr) | Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| MY159172A (en) | Inhalable particles comprising tiotropium | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| MX2009004198A (es) | Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea. | |
| MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
| MA30470B1 (fr) | Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste. | |
| MA30779B1 (fr) | Comprimes pediatriques de capecitabine | |
| MY207466A (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| Pappas et al. | The common cold and decongestant therapy | |
| ATE521343T1 (de) | Im mund zerfallende zusammensetzungen von rasagilin | |
| JP2024508373A (ja) | 固体医薬組成物および固体医薬組成物を生成する方法 | |
| Molina et al. | Evaluation of mercury contamination in patients and water during amalgam removal | |
| Färber, T. Stratz, W. Brückle, M. Späth, D. Pongratz, J. Lautenschläger, I. Kötter, B. Zöller, H.-H. Peter, G. Neeck, R. Alten, W. Müller | Efficacy and tolerability of tropisetron in primary fibromyalgia-a highly selective and competitive 5-HT3 receptor antagonist | |
| MA37953A1 (fr) | Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase | |
| Blakley et al. | Deafness associated with acetaminophen and codeine abuse. | |
| Villarreal et al. | Duloxetine in military posttraumatic stress disorder | |
| Shine et al. | Solitary fibrous tumor of the floor of the mouth: case report and review of the literature | |
| Goerdt et al. | Effects of Phenytoin on Plasma High‐Density Lipoprotein Cholesterol Levels in Men with Low Levels of High‐Density Lipoprotein Cholesterol | |
| Hassan et al. | Effect of hydroxyurea on clinical and laboratory parameters of sickle cell anaemia patients in North–West Nigeria | |
| MA32029B1 (fr) | Vaccins contre la malaria | |
| Reisner et al. | Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD | |
| Kaya et al. | Severe hyponatremia, epistaxis, and fluoxetine |